Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.

Saved in:
Bibliographic Details
Title: Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
Authors: Pfeifer Serrahima J; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Zhang C; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany.; Partner Site Frankfurt/Mainz, German Cancer Consortium (DKTK), Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Oberoi P; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany.; Partner Site Frankfurt/Mainz, German Cancer Consortium (DKTK), Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Bodden M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Röder J; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany., Arndt C; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Feldmann A; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Kiefer A; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Prüfer M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Kühnel I; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Tonn T; Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.; Partner Site Dresden, German Cancer Consortium (DKTK), Dresden, Germany.; Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany., Bachmann M; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Partner Site Dresden, German Cancer Consortium (DKTK), Dresden, Germany.; National Center for Tumor Diseases (NCT) and Tumor Immunology, University Cancer Center (UCC) Carl Gustav Carus, TU Dresden, Dresden, Germany., Wels WS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany. wels@gsh.uni-frankfurt.de.; Partner Site Frankfurt/Mainz, German Cancer Consortium (DKTK), Frankfurt, Germany. wels@gsh.uni-frankfurt.de.; German Cancer Research Center (DKFZ), Heidelberg, Germany. wels@gsh.uni-frankfurt.de.; Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany. wels@gsh.uni-frankfurt.de.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Sep; Vol. 72 (9), pp. 2905-2918. Date of Electronic Publication: 2023 Jan 23.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1432-0851
DOI:10.1007/s00262-023-03374-x